For diagnosed deficiency, weekly for 6 to 8 weeks, then biweekly, then monthly maintenance based on follow-up labs
Aunque no son idnticas a las versiones de marca, ofrecen una alternativa con los mismos principios activos a un costo generalmente ms bajo, haciendo el tratamiento ms accesible para quienes lo necesitan
Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrated remarkable efficacy in the SURMOUNT-OSA trial, reducing moderate-to-severe OSA severity by 62.8% compared to placebo
Protein needs vary by individual, and an RDN can help determine appropriate targets based on weight, activity level, and health status
By the end of week one, you have not yet reached steady-state levels